Completed PHASE2 INTERVENTIONAL 2-arm NCT01582347

Transfer of Subjects From Subutex/Suboxone to RBP-6300

A Randomized, Double-blind, Double-dummy, Active-drug-controlled, Parallel-group, Multicentre Acceptability and Safety Study of the Transfer From Subutex/Suboxone to RBP-6300 in Opioid-dependent Subjects

Sponsor: Indivior Inc.

Conditions Opioid Related Disorder

Interventions Placebo for RBP-6300 Placebo for Subutex®/Suboxone® RBP-6300 Subutex®/Suboxone®

Updated 8 times since 2017 Last updated: Jan 19, 2017 Started: Mar 31, 2012 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Opioid Related Disorder and is currently completed. Indivior Inc. leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indivior Inc.

Data source: Indivior Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austria, Austria , Bremen, Germany , Essen, Germany , Kassel, Germany , Linz, Austria , Munich, Germany , Oldenburg, Germany , Prague, Czechia , Regensburg, Germany , Salzburg, Austria and 5 more locations